The following table reconciles net loss per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2013Low HighNet Loss Per Share$
(0.27)Stock Compensation Expense0.420.42Amortization of Purchased Intangible Assets0.060.06Non-GAAP Measure of Net Income Per Share$
.21Accessing Cepheid's 2013 Second Quarter Results Conference CallThe Company will host a management presentation at 2 p.m. Pacific Time on Thursday, July 18, 2013, to discuss the results. To access the live webcast, please visit Cepheid's website at http://ir.cepheid.com at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.
About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
Use of Non-GAAP MeasuresThe Company has supplemented its report
Copyright©2012 PR Newswire.
All rights reserved